Why the study?
Statin intolerance is frequently documented in medical records but rarely objectively confirmed, leaving the rate of true statin intolerance and its clinical impact uncertain in peripheral artery disease.
Does true versus overdiagnosed statin intolerance affect lipid-lowering therapy use and mortality in patients with peripheral artery disease?
Does true versus overdiagnosed statin intolerance affect lipid-lowering therapy use and mortality in patients with peripheral artery disease?
Overdiagnosis of statin intolerance in PAD patients is common and is associated with underuse of effective lipid-lowering therapies and increased mortality.
Answers are grounded in this paper and cite their sources.
Statin intolerance labeling may shape therapy escalation and survival in PAD; leaves open causal effects of classification on outcomes.
Background: Statin intolerance (SI) is often documented in patients’ charts but rarely confirmed by objective methods. Objective: We aimed to identify the rate of true SI in a large population with peripheral artery disease (PAD) as well as the subsequent use of such drugs and the impact on cardiovascular outcomes. Methods: Patients with PAD and reported SI were retrospectively classified in those with “probable/possible” (pp) and “unlikely” (u) SI, after the application of the “Statin Myalgia Clinical Index Score” (SAMS-CI). Both groups were compared after 62 months (date of observation period?). Results: Among the 4,505 included patients, 139 (3%) had been reported as having SI. Of those, 33 (24%) had ppSI, and 106 (76%) had uSI. During the observation period, statin use decreased in patients with both ppSI (from 97% to 21%; p < 0.0001) and uSI (from 87% to 53%; p < 0.0001). At the end of the observation period, patients with ppSI more often received PCSK9 inhibitors (55% vs. 7%; p < 0.0001), had a stronger decrease in LDL-C from baseline to follow-up (1.82 ± 1.69 mmol/L vs. 0.85 ± 1.41 mmol/L; p < 0.01), and a lower rate of mortality (3% vs. 21%; p = 0.04) than those with uSI. Conclusions: SI is low in PAD patients (3.1%), with only one quarter fulfilling the criteria of ppSI. The overdiagnosis of SI is related to an underuse of statins and an increased mortality in a short time period.
No takes yet. Share an insight, caveat, or question.
Dopheide et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: